

## Journals:

1. Van Kampen J, Baranowski DC, Robertson HA, Shaw CA, Kay DK. The progressive BSSG rat model of Parkinson's : recapitulating multiple key features of the human disease. *PLOS*. <http://dx.doi.org.insert details>. (2015).
2. Zwiegers P, Shaw CA. Disparity of outcomes: the limits of modeling amyotrophic lateral sclerosis in murine models and translating results clinically. *J. Controversies in BioMed Res*. 1(1):4-22. (2015).
3. Crepeaux G, Eidi H, David M-O, Tzavara E, Giros B, Exley C, Curmi PA, Shaw CA, Gherardi RK, Cadusseau J. Highly delayed systemic translocation of aluminium-based adjuvant in CD1 mice following intramuscular injections. *J. Inorg. Biochem*. (2015).  
<http://dx.doi.org/10.1016/j.jinogbio.2015.07.004>
4. Shaw CA, Li D, Tomljenovic L. Are there negative CNS impacts of aluminum adjuvants in vaccines and immunotherapy? *Immunotherapy*. 6 (10):1055-1071. (2014).
5. Van Kampen, J.M., Baranowski, D.C., Shaw, C.A., and D.G Kay. Panax ginseng is neuroprotective in a novel progressive model of Parkinson's disease. *Exp Gerontol*, 50(2014):95-105. (2014).
6. Shaw CA, Seneff S, Kette SD, Tomljenovic L, Oller Jr JW, Davidson RM. Aluminum-induced entropy in biological systems: Implications for neurological disease. *J Toxicology*. Volume 2014, Article ID 491316. <http://dx.doi.org/10.1155/2014/401316>. (2014).
7. Shaw CA, Sheth S, Li D, Tomljenovic L. Etiology of autism spectrum disorders: Genes, environment, or both? *OA Autism*. 10:2(2):11. (2014).
8. Zwiegers P, Lee G, and Shaw CA. Reduction in hSOD1 copy number significantly impacts ALS phenotype presentation in G37R (line 29) mice: implications for the assessment of putative therapeutic agents. *Journal of Negative Results in BioMedicine*. 13:14. Doi:10.1186/1477-5751-13-14. (2014).
9. Shaw CA, Kette SD, Davidson RM, Seneff S. Aluminum's role in CNS-immune system interactions leading to neurological disorders. *Immunome Res*. 9:1. <http://dx.doi.org/10.4172/1745-7580.1000069>.(2013).
10. Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y. Human papilloma virus vaccine and primary ovarian failure: Another facet of the Autoimmune/Inflammatory Syndrome Induced by Adjuvants. *Am J Reproductive Immunology*. 70(4):309-16. (2013).
11. Shaw CA, Marler TE. Aluminum and the human diet revisited. In: *Communicative & Integrative Biology; Landes Bioscience*. 6:e26369. (2013).
12. Tomljenovic L, Wilyman J, Vanamee E, Bark T, Shaw CA. (Letter) HPV vaccine and cancer prevention, science versus activism. *Infectious Agents and Cancer*. 8(1):6. (2013).
13. Shaw CA, Tomljenovic L. Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity. *Immunol Res*. DOI 10.1007/s12026-013-8403-1. (2013).
14. Shaw CA, Li Y, Tomljenovic L. Administration of aluminum to neonatal mice in vaccine in vaccine-relevant amounts is associated with adverse long term neurological outcomes. *J Inorg Chem*. <http://dx.doi.org/10.1016/j.jinorgbio.2013.07.022>. (2013).
15. Tomljenovic L, Spinosa JP, Shaw CA. Human Papillomavirus (HPV) Vaccines an option for preventing cervical malignancies: (How) Effective and safe? *Current Pharm Design*. 19(8):1466-87. (2013).
16. Tomljenovic L, Shaw AC. Too Fast or Not Too Fast: The FDA's Approval of Merck's HPV Vaccine Gardasil. *J Law Med Ethics*. Fall: 673-681. (2012).

17. Tomljenovic L, Dorea JG, Shaw AC. Commentary: A link between mercury exposure, autism spectrum disorder and other neurological disorders? Implications for thimerosal-containing vaccines. *JoDD*. 18(1):34-42. (2012).
18. Tomljenovic L, Shaw CA. Death after quadrivalent human papillomavirus (HPV) vaccination: causal or coincidental? *Pharma Reg Affairs*. S12:001. Doi:10.4172/2167-7689.S12-001. (2012).
19. Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. *Lupus*. 21:223-230. (2012)
20. Lee G, Shaw AC. Early exposure to environmental toxin contributes to neuronal vulnerability and axonal pathology in a model of familial ALS. *Neuroscience Medicine*. Doi:10.4236/nm.2012. (2012).
21. Tomljenovic L and Shaw CA. Who profits from uncritical acceptance of biased estimates of vaccine efficacy and safety? *AJPH*. Doi: 10.2105/AJPH.2012.300827. (2012).
22. Tomljenovic L and Shaw CA. No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil? *J Internal Medicine*. Doi.10.1111/j.1365-2796.2012.025551.x. (2012).
23. Tomljenovic L and Shaw CA. Editorial, Special Issue: The Biochemistry/Toxicity of Aluminum. *Current Inorganic Chemistry*. 2(1): 1-2. (2012).
24. Tomljenovic L and Shaw CA. Mandatory HPV vaccination. [Letter to Editor]. *JAMA*. 307(3): 254; Author reply 254-5. (2012).
25. Tomljenovic L and Shaw CA. Microglia-mediated immunoexcitotoxicity, a key player in traumatic brain injury? [Commentary]. *Surg Neuro Int*. 2(107). (2011).
26. Tomljenovic L and Shaw CA. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: Are they at odds? *Annals of Medicine*. 1 – 12, DOI: 10.3109/07853890.2011.645353. (2011).
27. Tomljenovic L and Shaw CA. One size fits all? *Vaccine*. Doi.10.1016/j.vaccine.2011.11.053. (2011).
28. Tomljenovic L and Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? *J Inorg Biochem*. 105(11):1489-99. (2011).
29. Tomljenovic L and Shaw CA. Aluminum vaccine adjuvants: Are they safe? *Current Medicinal Chemistry*. 18:2630 – 2637. (2011).
30. Panov A, Kubalik N, Brooks BR, and Shaw CA. In vitro effects of cholesterol  $\beta$ -D-glucoside, cholesterol and cycad glucosides on respiration and reactive oxygen species generation in brain mitochondria. *J. Membrane Biol*. DOI 10:1007/s00232- 10-9307-7. (2010).
31. Marler TE, Snyder LR, and Shaw CA. Cycas micronesica (Cycadales) plants devoid of endophytic cyanobacteria increase in b-methylamino-L-alanine. *Toxicon*. 56: 563-568. (2010).
32. Shen W-B, McDowell KA, Siebert AA, Clark SM, Dugger NV, Valentino KM, Jinnah A, Sztalryd C, Fishman PS, Shaw CA, Jafri MS, and Yarowsky PJ. Environmental neurotoxin-induced progressive model of parkinsonism in rats. *Annals of Neurology*. 68(1):70-80. (2010).
33. Tasker RA, Adams-Marriott AL, and Shaw CA. New animal models of progressive neurodegeneration: tools for identifying presymptomatic therapeutic targets. *The EMPA Journal*. DOI: 10.1007/S13167-010-0019-0. (2010).
34. Marler T and Shaw CA. Distribution of free and glycosylated sterols within Cycas micronesica plants. *Scientia Horticulturae*. Doi.1016/j.scienta.2009.11.009. (2009).
35. Ryan CL, Baranowski DC, Chitramuthu BP, Malik S, Li Z, Cao M, Minotti S, D Durham HD, Kay DG, Shaw CA, Bennett HPJ, and Bateman A. Progranulin is expressed within motor neurons and promotes neuronal cell survival. *BMC Neuroscience*. Doi.10.1186/1471-2202-10-130. (2009).
36. Shaw CA, Pelech S, and Ly PTT. Paradoxical responses to neurotoxic glycosides: insights from a cellular model of ALS-PDC. *Neurobiology of Lipids*. 8,1. (2009).

37. Snyder LR, Cruz-Aguado R, Sadilek M, Galasko D, Shaw CA, and Montine TJ. Parkinson-dementia complex and development of a new stable isotope dilution assay for BMAA detection in tissue. *Toxicology and Applied Pharmacology*. 240: 180-188. (2009).
38. Shaw CA and Petrik MS. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. *J Inorganic Biochem*. 103 (11): 1555-62. (2009).
39. Cruz-Aguado R and Shaw CA. The ALS/PDC syndrome of Guam and the cycad hypothesis. Correspondence. *Neurology*. 72(5):473-477. (2009).
40. Lee G, Chau T, and Shaw CA. The primary locus of motor neuron death in an ALS-PDC mouse model. *NeuroReport*. 20 (14): 1284-1289. (2009).
41. Marler T and Shaw CA. Phenotypic characteristics as predictors of phytosterols in mature *Cycas micronesica* seeds. *HortScience*. 44 (3):725-729. (2009).
42. Marler T and Shaw CA. Free and glycosylated sterol bioaccumulation in developing *Cycas micronesica* seeds. *Food Chem*. 115: 615-619. (2009).
43. Snyder RL, Cruz-Aguado R, Sadilek M, Glasko D, Shaw C, and Montine TJ. Lack of cerebral BMAA in human cerebral cortex. *Neurology*. 72 (15):1360-1361. (2009).
44. Ly PTT, Pelech S, and Shaw CA. Cholesteryl glucoside stimulates activation of protein kinase B/Akt in motor neuron-derived NSC34 cell line. *Neurobiology of Lipids*. 7, 4. (2008).
45. Janáky R, Shaw CA, Oja SS, and Saransaari P. Taurine release in developing mouse hippocampus is modulated by glutathione and glutathione derivatives. *Amino Acids*. 34(1): 75-80. (2008).
46. Shaw CA and Höglinger GU. Neurodegenerative diseases: neurotoxins as sufficient etiologic agents? *J Neuromolecular Medicine*. 10(1): 1-9. (2008).
47. Tabata RC, Wilson JMB, Van Kampen JM, Cashman N, and Shaw CA. Dietary sterol glucosides are neurotoxic to motor neurons and induce an ALS-PDC phenotype. *J Neuromolecular Medicine*. 10(1): 24-39. (2008).
48. Petrik MS, Wilson JMB, Grant SC, Blackband SJ, Tabata RC, Shan X, Krieger C, and Shaw CA. Magnetic resonance microscopy and immunohistochemistry of the CNS of the mutant SOD murine model of ALS reveals widespread neural deficits. *J Neuromolecular Medicine*. 9(3): 216-229, (2007).
49. Ly PTT, Singh S, and Shaw CA. Novel environmental toxins: steryl glucosides as a potential etiological factor for age-related neurodegenerative diseases. *J Neurosci. Res*. 85(2): 231-237. (2007).
50. Wilson JMB and Shaw CA. Late appearance of glutamate transporter defects in a murine model of ALS-parkinsonism dementia complex. *Neurochem Int*. 50(7-8): 1067-1077. (2007).
51. Marler TE, Lee V, and Shaw CA. Storage does not influence steryl glucoside concentration in *Cycas micronesica* seeds. *Hortscience Science* 42(3): 626-628. (2007).
52. Marler TE, Lee V, and Shaw CA. Habitat Heterogeneity of *Cycas micronesica* Seed Chemistry in Guam's Forest. *Micronesica* 39(2): 297-314. (2007).
53. Petrik MS, Wong MC, Tabata RC, Garry RF, and Shaw CA. Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. *J Neuromolecular Medicine* 9: 83-100. (2007).
54. Cruz-Aguado R, Winkler D, and Shaw CA. Lack of behavioral and neuropathological effects of dietary b-methylaminoalanine (BMAA) in mice. *Pharmacol, Biochem, Behav*. 84: 294-299. (2006).
55. Marler TE, Lee V, Chung J, and Shaw CA. Steryl glucoside concentration declines with *Cycas micronesica* seed age. *Funct. Plant Biol*. 33:857-862. (2006)
56. Wilson JMB and Shaw CA. Commentary on Return of the cycad hypothesis – does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health? *Neuropathology and Applied Neurobiology* 32: 341-343. (2006).

57. Marler TE, Lee V, and Shaw CA. Cycad toxins and Neurological Diseases in Guam: defining theoretical and experimental standards for correlation human disease with environmental toxins. *Horticultural Science* 33: 1598-1606. (2005).
58. Marler TE, Lee V, and Shaw CA. Spatial variation of steryl glucosides in *Cycas micronesica* plants-within and among plant sampling procedures. *Horticultural Science* 40: 1607-1611. (2005).
59. Schulz JD, Hawkes EL, and Shaw CA. Cycad toxins, helicobacter pylori and parkinsonism: cholesterol glucosides as the common denominator. *Medical Hypothesis* 40: 1598-1606. (2005).
60. Wilson JMB, Petrik MS, Grant SC, Blackband SJ, Lai J, and Shaw CA. Quantitative measurement of neurodegeneration in an ALS-PDC model using MR microscopy. *Neuroimage* 23(1):336-343. (2004).
61. Wilson JMB, Petrik MS, Moghadasian M, and Shaw CA. Examining the role of apoE in neurodegenerative disorders using an environmentally-induced murine model of ALS-PDC. *Canadian Journal of Physiology and Pharmacology* 83(2):131-41. (2005).
62. Normen L, Moghadasian M H, Shaw C A, Fink C S, and Awad A B. Combination of phytosterols and omega-3 fatty acids: A potential strategy to promote cardiovascular health. *Journal of Medicinal Chemistry* 2(1): 1-12. (2004).
63. Schulz JD, Wilson JMB, and Shaw CA. A murine model of ALS-PDC with behavioral and neuropathological features of parkinsonism. *Annals of the New York Academy of Sciences* 991: 326-329. (2003).
64. Shaw CA and Wilson JMB. Analysis of neurological disease in 4 dimensions: Insight from ALS-PDC epidemiology and animal models. *Neurosci Biobehav Rev.* Oct. 27(6): 493-505. (2003).
65. Wilson JMB, Khabazian I, Pow D V, Craig U-K, and Shaw CA. Decrease in glial glutamate transporter variants and excitatory amino acid receptor down-regulation in a murine model of ALS-PDC. *NeuroMolecular Medicine.* 3(2): 41-53. (2003).
66. Shaw CA, Wilson JMB, and Khabazian I. Reverse engineering neurological disease. *Interjournal, Brief Article* 592 (available online). (2003).
67. Shaw CA. Do neurodegenerative cascades in Parkinson's disease really reflect bottom-up processing? *Behavioral and Brain Sciences.* (2003).
68. Khabazian I, Bains JS, Williams DE, Cheung J, Wilson JMB, Pasqualotto BA, Pelech SL, Andersen RJ, Wang Y-T, Liu L, Nagai A, Kim SU, Craig U-K, and Shaw CA. Isolation of various forms of sterol  $\beta$ -d-glucoside from the seed of *Cycas circinalis*: neurotoxicity and implications for ALS-PDC. *J. Neurochem.* 82: 1-13. (2002).
69. Wilson JMB, Khabazian I, Wong MC, Seyedalikhani A, Bains JS, Pasqualotto BA, Williams DE, Andersen RJ, Simpson R J, Smith R, Craig UK, Kurland LT, and Shaw CA. Behavioral and neurological correlates of ALS-parkinsonism dementia complex in adult mice fed washed cycad flour. *J. Neuromol. Med.* 1(3): 207-222. (2002).
70. Shaw CA and Bains JS. Synergistic versus antagonistic actions of glutamate and glutathione: the role of excitotoxicity and oxidative stress in neuronal disease. *Cell. & Mol. Biol.*, 48(2): 127-36. (2002).
71. Janaky R, Shaw CA, Varga V, Hermann A, Dohovics R, Saransaari P, and Oja SS. Specific glutathione binding sites in pig cerebral cortex. *Neurosci.*, 95(2): 617-624. (2000).
72. Janaky R, Ogita K, Pasqualotto BA, Bains JS, Oja SS, Yoneda Y, and Shaw CA. Glutathione and signal transduction in the mammalian CNS. *J. Neurochem.*, 73: 889-902. (1999).
73. Shaw CA, Bains JS, Pasqualotto BA, and Curry K. Methionine sufoximine shows excitotoxic actions in rat cortical slices. *Can. J. Physiol. Pharmacol.* 77: 871 – 877. (1999).
74. Shaw CA, Pasqualotto BA, Curry K, Kim SU, LaCompte KA, and Langmuir ME. A novel fluorescent GSH adduct binds to the NMDA receptor. *J. Neurosci. Meth.*, 93: 21-26, (1999).

75. McEachern JC and Shaw CA. Lifting of MMT ban is not justified by lack of scientific proof. *CCPA Monitor*. Nov.: 14-16. (1998).
76. Shaw CA and Bains JS. Did consumption of flour treated by the agene process contribute to the incidence of neurological disease? *Med. Hyp.*, 51: 477-481. (1998).
77. Wagey R, Krieger C, and Shaw CA. Abnormal dephosphorylation effect on NMDA receptors in ALS spinal cord, *Neurobiol. of Disease*, 4: 350-355. (1997).
78. Shaw CA, Pasqualotto BA, and Curry K. Glutathione-induced sodium currents in neocortex, *NeuroReport*, 7:1149-1152. (1996).
79. Lanius RA, Paddon HB, Mezei M, Wagey R, Krieger C, Pelech SL, and Shaw CA. A role for amplified PKC in the pathogenesis of ALS, *J. Neurochem.* , 65:927-930. (1995).
80. Hendrickson A., March D, Richards G, Erickson A, and Shaw CA. Coincidental appearance of the  $\alpha 1$  subunit of the GABA<sub>A</sub> receptor and the type I benzodiazepine receptor near birth in macaque monkey visual cortex, *Int. J. Dev. Neurosci.* , 12:299-314. (1994).
81. Lanius RA, Shaw CA, Wagey R, and Krieger C. Characterization, distribution, and protein kinase C-mediated regulation of [<sup>35</sup>S]-glutathione binding sites in mouse and human spinal cord, *J. Neurochem.*, 63: 155-160. (1994).
82. Krieger C, Lai R, Mitsumoto H, and Shaw CA. The wobbler mouse: quantitative autoradiography of glutamatergic ligand binding sites in spinal cord, *Neurodegen.*, 2: 9-17. (1993).
83. Krieger C, Wagey R, Lanius RA, and Shaw CA. Activation of protein kinase C restores inactivated NMDA receptors in spinal cords from patients with amyotrophic lateral sclerosis, *NeuroReport*, 4: 931-934. (1993).
84. Krieger C, Wagey R, and Shaw CA. A decrease in [<sup>3</sup>H]-MK801 binding in amyotrophic lateral sclerosis, *Neurosci. Lett.*, 159: 191-194. (1993).
85. Lanius RA, Krieger C, Wagey, and Shaw CA. Increased glutathione binding sites in spinal cord from patients with sporadic amyotrophic lateral sclerosis, *Neurosci. Lett.*, 163: 89-92. (1993).
86. Lanius RA, Pasqualotto BA, and Shaw CA. A novel mechanism of AMPA receptor regulation: ionically-triggered kinases and phosphatases, *NeuroReport*, 4: 795-798. (1993).
87. Lanius RA, Pasqualotto BA, and Shaw CA. GABA<sub>A</sub> receptor regulation by a Cl<sup>-</sup> dependent kinase and a Na<sup>+</sup>- dependent phosphatase, *Mol. Brain Res.*, 20: 192-198. (1993).
88. Lanius RA and Shaw CA. High-affinity kainate binding sites in living slices of rat neocortex: characteristics and regulation, *Neurosci.*, 55: 139-145. (1993).
89. March D and Shaw CA. Fetal, neonatal, and adult expression of benzodiazepine receptor subtypes in human visual cortex, *Eur. J. Pharmacol.* , 236: 333-33. (1993).
90. Pasqualotto BA, Lanius RA, and Shaw CA. Regulation of GABA<sub>A</sub> and AMPA receptors by agonist and depolarizing stimulation requires phosphatase or kinase activity, *NeuroReport*, 4: 457-460. (1993).
91. Van Huizen F, March D, and Shaw CA. Muscarinic receptor characteristics and regulation in rat cerebral cortex: changes during development, aging and the estrous cycle, *Eur. J. Neurosci.* , 6: 237-247. (1993).
92. Guo N and Shaw CA. Characteristics and localization of glutathione binding sites in cultured astrocytes, *Mol. Brain Res.*, 15: 207-215. (1992).
93. Guo N, McIntosh C, and Shaw CA. Glutathione: new candidate neuropeptide in the central nervous system, *Neurosci.* 51: 835-842. (1992).
94. Lanius R A and Shaw CA. Characterization and regulation of a high-affinity [<sup>3</sup>H]-CNQX labeled AMPA receptor in rat neocortex, *Mol. Brain Res.*, 15: 256-262. (1992).

95. Shaw CA and Lanius RA. Reversible kinase/phosphatase regulation of brain amino acid receptor in postnatal development, *Dev. Brain Res.* 70: 153-161. (1992).
96. Shaw CA and Scarth BA. Age-dependent regulation of GABA<sub>A</sub> receptors in neocortex, *Mol. Brain Res.* 14: 207-212. (1992).
97. Shaw CA, Pasqualotto BA, and Lanius RA. A role for kinase/phosphatase action in the regulation of brain amino acid receptors, *Mol. Neuropharm.* 2: 297-302. (1992).
98. Shaw C, Cameron L, March D, Cynader M, Zielinski B, and Hendrickson A. Pre- and postnatal developmental of GABA receptors in macaca monkey visual cortex. *J. Neurosci.* 11: 3947-3959. (1991).
99. Shaw C and Scarth B. Characterization and differential regulation of GABA<sub>A</sub> and benzodiazepine receptors in rat neocortex. *Mol. Brain Res.* 11:273-282. (1991).
100. Cumming P, Shaw C, and Vincent S. The high-affinity histamine binding site in rat brain. *Synapse*, 8:144-151. (1991).
101. Jia W-G, Shaw C, Van Huizen F, and Cynader M. Phorbol 12, 13-dibutyrate regulates muscarinic receptors in rat cerebral cortical slices by activating protein kinase C. *Mol. Brain Res.* 5:311-315. (1989).
102. Shaw C, Prusky F, Van Hizen F, and Cynader M. Differential effects of quinolinic acid lesions on muscarinic acetylcholine receptors in cat visual Cortex during postnatal development. *Brain Res. Bulletin*, 22:771-776. (1989).
103. Shaw C, Van Huizen F, Cynader M, and Wilkinson M. A role for potassium channels in the regulation of cortical muscarinic acetylcholine receptors in an *in vitro* slice preparation. *Mol. Brain Res.*, 5:71-83. (1989).
104. Van Huizen F, Shaw C, Wilkinson M, and Cynader M. Characterization of muscarinic acetylcholine receptors in rat cerebral cortex slices with concomitant morphological and physiological assessment of tissue viability. *Mol. Brain Res.*, 5:59-69. (1989).
105. Needler MC, Wilkinson M, Prusky G, Shaw C, and Cynader M. Development of phorbol ester (protein kinase C) binding sites in cat visual cortex. *Dev. Brain Res.* 42:217-227. (1988).
106. Prusky GT, Shaw C, and Cynader M. The distribution and ontogenesis of [<sup>3</sup>H]- nicotine binding sites in cat visual cortex. *Dev. Brain Res.*, 42:217-227. (1988).
107. Sampson SM, Shaw C, Wilkinson M, and Rasmusson DD. Sensory deafferentation fails to modify muscarinic receptor binding in raccoon somatosensory cortex. *Brain Res. Bulletin.*, 20:597-601. (1988).
108. Shaw C and Cynader M. Unilateral eyelid suture increases GABA<sub>A</sub> receptors in cat visual cortex. *Dev. Brain Res.*, 40:148-153. (1988).
109. Shaw C, Prusky G, and Cynader M. Surgical undercutting prevents receptor redistribution in developing kitten visual cortex. *Visual Neurosci*, 1:205-210. (1988).
110. Van Huizen F, Wilkinson M, Cynader M, and Shaw C. Sodium channel toxins veratrine and vertridine modify opioid and muscarinic but not  $\beta$ -adrenergic binding sites in brain slices. *Brain Res. Bulletin*, 21: 129-132. (1988).
111. Prusky G, Shaw C, and Cynader M. Nicotine receptors are located on lateral geniculate nucleus terminals in cat visual cortex. *Brain Res.*, 412: 131-138. (1987).
112. Shaw C, Aoki C, Wilkinson M, Prusky G, and Cynader M. Benzodiazepine receptors in cat visual cortex: ontogenesis of normal characteristics and the effects of dark rearing. *Dev. Brain Res.*, 37: 67-76. (1987).

113. Shaw C, Kirby S, Feran M, Lepore F, Guillimot JP, and Cynader M. Anomalous 2-deoxyglucose uptake and acetylcholine-esterase activity in cat LGN after optic chiasm section. *Exp. Biology*. 47: 43-48. (1987).
114. Shaw C and Cynader M. Laminar distribution of receptors in monkey (*Macaca fascicularis*) geniculostriate system. *J. Comp. Neurology*. 248: 301-312. (1986)
115. Shaw C, Hall SE, and Cynader M. Characterization, distribution and ontogenesis of adenosine binding sites in cat visual cortex. *J. Neurosci.*, 6: 3218-3228. (1986).
116. Shaw C and Cynader M. Alterations in the laminar distribution of pentagastrin binding sites in cat visual cortex during postnatal development. *Dev. Brain Res.*, 20: 132-36. (1985).
117. Shaw C, Needler MC, Wilkinson M, Aoki C, and Cynader M. Modification of neurotransmitter receptor sensitivity in cat visual cortex during the critical period. *Dev. Brain Res*. 22: 67-73. (1985)
118. Needler MC, Shaw C, and Cynader M. Characteristics and distribution of muscimol binding sites in cat visual cortex. *Brain Res*. 308: 347-353. (1984)
119. Shaw C and Cynader M. Disruption of cortical activity prevents changes of ocular dominance in monocularly-deprived kittens. *Nature*. 308: 731-734. (1984)
120. Shaw C, Needler MC, and Cynader M. Ontogenesis of [<sup>3</sup>H]-muscimol binding sites in cat visual cortex. *Brain Res. Bulletin*. 13: 331-334. (1984)
121. Shaw C, Needler MC, and Cynader M. Ontogenesis of muscarinic acetylcholine binding sites in cat visual cortex: reversal of laminar specific distribution during the critical period. *Dev. Brain Res*. 14: 295-299. (1984)
122. Shaw C, Needler MC, Wilkinson M, Aoki C, and Cynader M. Alterations in receptor number, affinity and laminar distribution in cat visual cortex during the critical period. *Prog. Neuropsychol. Biol. Psych*. 8: 627-634. (1984).
123. Wilkinson M, Shaw C, Khan I, and Cynader M. Ontogenesis of  $\beta$ -adrenergic binding sites in kitten visual cortex and the effects of visual deprivation. *Dev. Brain Res*. 7: 349-352. (1983).
124. Shaw C and Teyler TJ. The neural circuitry of the neocortex examined in the in vitro brain slice preparation. *Brain Res*. 243: 35-47. (1982).
125. Shaw C, Hanani M, and Hillman P. The effects of  $Mn^{++}$  and  $Ca^{++}$  on the prolonged depolarizing after potential in barnacle photoreceptor. *Biophys. Struct. Mech*. 5: 223-230. (1979).
126. Hanani M and Shaw C. A potassium contribution to the response of the barnacle photoreceptor. *J. Physiol*. 270: 151-163. (1977).
127. Shaw C, Yinon U, and Auerbach E. Receptive fields and response properties of neurons of the rat visual cortex. *Vision Res*. 15: 42-49. (1975).
128. Shaw C, Yinon U, and Auerbach E. Single unit activity in rat visual cortex. *Vision Res*. 14: 311-313. (1974).
129. Shaw C, Yinon U, and Auerbach E. Diminution of evoked neuronal activity in rat visual cortex after pattern deprivation. *Exp. Neurology*. 45: 42-49. (1974).
130. Teyler T, Shaw C, and Thompson RF. Unit responses to moving visual stimuli in the motor cortex of the cat. *Science*. 176: 811-813. (1972).

#### **Books:**

1. Shaw, C. A. *Neural Dynamics of Neurological Disease*. John Wiley and Sons. Boston, USA. Expected publication 2016.
2. Shaw, C.A. *Stealing the Mind: The Hidden History of Neurological Disease*, under review, 2008.